Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ruizhe He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5355-3889; OpenAlex author ID A5074421421. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  2. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  3. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
  4. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  5. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  6. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  7. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  8. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.051↗
  9. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. First author DOI 10.1038/s41419-019-2072-5↗
  10. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  11. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-018-34094-3↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minwei Yang · 10 shared papers, 2018–2023 · strength 1.13
  2. Yan‐Miao Huo · 8 shared papers, 2019–2023 · strength 0.95
  3. Yongwei Sun · 8 shared papers, 2019–2023 · strength 0.89
  4. Xueliang Fu · 8 shared papers, 2018–2023 · strength 0.84
  5. Jian‐Yu Yang · 7 shared papers, 2019–2023 · strength 0.76
  6. Dejun Liu · 5 shared papers, 2019–2023 · strength 0.60
  7. Rong Hua · 5 shared papers, 2019–2022 · strength 0.48
  8. Jia-Hao Zheng · 3 shared papers, 2022–2023 · strength 0.47
  9. Hong‐Fei Yao · 3 shared papers, 2022–2023 · strength 0.47
  10. Jian Yang · 3 shared papers, 2022–2023 · strength 0.40
  11. Shu‐Heng Jiang · 3 shared papers, 2020–2022 · strength 0.32
  12. Dapeng Xu · 2 shared papers, 2022–2023 · strength 0.32
  13. Ping Lu · 3 shared papers, 2019–2022 · strength 0.30
  14. Ningning Niu · 3 shared papers, 2019–2022 · strength 0.30
  15. Jing Xue · 3 shared papers, 2019–2022 · strength 0.30
  16. Yongsheng Jiang · 3 shared papers, 2019–2022 · strength 0.28
  17. Wei Liu · 2 shared papers, 2021–2022 · strength 0.24
  18. Zhigang Zhang · 3 shared papers, 2019–2020 · strength 0.24
  19. Junfeng Zhang · 2 shared papers, 2019–2023 · strength 0.23
  20. Meilian Zhuo · 1 shared paper, 2026 · strength 0.21
  21. Xianlin Han · 1 shared paper, 2026 · strength 0.21
  22. Mingyang Liu · 1 shared paper, 2026 · strength 0.21
  23. Mo Chen · 1 shared paper, 2026 · strength 0.21
  24. Junya Peng · 1 shared paper, 2026 · strength 0.21
  25. Menghua Dai · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.